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Abstract 
Glioblastoma (GB) is the most frequent and aggressive tumor of the central nervous system. There 
is currently growing interest in proteomic studies of GB, particularly with the aim of identifying 
new prognostic or therapeutic response markers. However, comparisons between different 
proteomic analyzes of GB have revealed few common differentiated proteins. The types of control 
samples used to identify such proteins may in part explain the different results obtained.  
We therefore tried to determine which control samples would be most suitable for GB proteomic 
studies. We used an isotope-coded protein labeling (ICPL) method followed by mass spectrometry 
to reveal and compare the protein patterns of two commonly used types of control sample: GB 
peritumoral brain zone samples (PBZ) from six patients and epilepsy surgery brain samples (EB) 
pooled from three patients. The data obtained were processed using AMEN software for network 
analysis. 
We identified 197 non-redundant proteins and 35 of them were differentially expressed. Among 
these 35 differentially expressed proteins, six were over-expressed in PBZ and 29 in EB, showing 
different proteomic patterns between the two samples. Surprisingly, EB appeared to display a 
tumoral-like expression pattern in comparison to PBZ. 
In our opinion, PBZ may be more appropriate control sample for GB proteomic analysis. 
 
Significance 
This manuscript describes an original study in which we used an isotope-coded protein labeling 
method followed by mass spectrometry to identify and compare the protein patterns in two types of 
sample commonly used as control for glioblastoma (GB) proteomic analysis: peritumoral brain 
zone and brain samples obtained during surgery for epilepsy. The choice of control samples is 
critical for identifying new pronostic and/or diagnostic markers in GB. 
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Introduction 
Glioblastoma (GB) is the most frequent and aggressive tumor of the central nervous system. 
Despite the development of new therapies, the prognosis remains poor, with a mean progression-
free survival of 7 months and an average survival of 12 to 15 months [1, 2]. Even following gross 
total resection and optimal adjuvant treatment, recurrence is extremely common, mainly from the 
margin of the resection cavity [3-5]. 
GB is a very hetererogenous groups of tumors [6], involving different zones; both genomic [7, 8] 
and proteomic [9-11] approaches have been used to study these tumors. These analyses led to the 
identification of different markers, allowing the characterization of different subtypes of GBs and 
tumoral mechanisms, and may serve as a basis for the development of new therapies focused on the 
molecular, genetic and proteomic particularities of GB. 
In one of our previous proteomic studies, we used an isotope-coded protein label (ICPL) method to 
compare three areas of GB: the tumor zone (TZ), the interface zone between the tumor and the 
parenchyma (IZ) and the peritumoral brain zone (PBZ). We successfully identified 35 proteins 
over-expressed in the core of the tumor by comparison with the periphery and showed that 23 of 
these belong to a cohesive network of physically interacting proteins linked to several cellular 
functions [10]. 
However, few of the 35 proteins that we found to be altered in TZ are the same as those identified 
by previous studies (Table 1). For example, Khalil [12] used 2DE with MALDI-TOF MS and LC-
MS/MS to analyze 30 GB samples with seven control samples obtained from epilepsy surgery for 
reference. Forty-six differentially expressed proteins were identified of which only ten proteins 
were in common with our study (β-actin, CKB, GDI1, ALDOA, 14-3-3γ, ATP5A1, ALB, GFAP, 
NEFL, ENO1). Except for β-actin, most of these proteins showed a different pattern of expression 
to that described in this previous study. Indeed, we found these proteins to be over-expressed in TZ 
versus PBZ whereas Khalil [12] observed under-expression in GB samples versus control epilepsy 
samples. To understand the apparent differences in the protein expression patterns between the two 
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studies, we conducted a bibliographical search for proteomic analyses of fresh brain tumor samples 
(reported in Table 1). This analysis revealed substantial heterogeneity in results associated with the 
different proteomic analysis techniques employed and the control tissues used. Indeed, differences 
in both the analytical methodologies and the control tissues used may explain the only weak 
similarities between proteomic patterns reported by the various studies. 
Obviously, normal live brain samples are not available to be used as control samples under all 
circumstancies, and consequently the control samples commonly used in GB proteomic studies 
include brain tissue obtained during surgery for epilepsy (EB) or from the walls of the resection 
cavity during GB surgery (PBZ), with the informed consent of the patient. 
However, it is unclear whether PBZ or EB brain samples, commonly used as controls, can be 
considered to be “normal” brain tissue, and therefore whether they are appropriate for proteomic 
comparisons and describing the differential proteomic expression pattern of brain tumors. 
The aim of this study was to analyze and compare the protein expression patterns of these two 
control tissues (PBZ versus EB) using the ICPL proteomic method, and to determine which is the 
most suitable for use as control tissue for proteomic analyses of brain tumors. 
 
Materials and Methods 
Clinical materials 
Six patients whose diagnosis of primary GB (WHO 2007 classification) was confirmed by a central 
committee of neuropathologists and three patients undergoing epilepsy surgery were included in the 
study. This study was approved by the relevant ethics committee (CPP Ouest II, Angers, France) 
and all patients signed an informed consent form for participation in this study.  
The tumoral zone and PBZ from GB were defined on preoperative T1 gadolinium-enhanced 3D 
MRI. Stereotaxic biopsies were performed in the operating theater, by computer-assisted 
neurosurgery (BrainLab®, La Défense, France). EB was obtained from cortical resection during  
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Table 1: Overview of the GB biopsy proteomic literature and comparison of the proteins identified 
with our previous study
*
 [10] 
GB: glioblastoma; AA: anaplastic astrocytoma; AO: anaplastic oligodendroglioma; oligo: oligodendroglioma; DNET: 
Dysembryoplastic neuroepithelial tumor; 2DGE: 2D Gel electrophoresis; ICPL: isotope coded protein labelling; LC-
ESI: liquid chromatography electrospray ionization; MALDI-TOF: matrix-assisted laser desorption ionization time of 
flight; nano-LC: nanoliquid chromatography; SELDI-TOF: surface enhanced laser desorption ionization time of flight; 
PBZ: peritumoral brain zone, EB: peripheral epilepsy surgery brain zone. 
Reference Year n WHO grade Method Control 
Proteins 
Differentially 
expressed 
Proteins 
in 
common* 
[27] 2011 5 GB 2DGE, MALDI-TOF 
MS, 2D-PAGE, 
Western Blot 
EB 22 4 
[28] 2009 27 GB Western Blot Cancer genome 
atlas 
55 1 
[29] 2009 1 GB HPLC-ESI-MS/MS PBZ 15 - 
[30] 2009 3 GB 2DGE, MALDI-TOF 
MS 
PBZ 8 1 
[12] 2007 41 24 primary GBs 
4 secondary GBs 
4 grade III 
2 grade II 
7 epilepsy 
2D-PAGE, 2DGE, 
MALDI-TOF MS 
EB 91 9 
[31] 2007 20 10 GBs 
10 controls 
Nano-LC prior to 
MALDI-TOF/TOF 
Samples from 
different patients 
with a variety of 
CNS conditions 
16 0 
[32] 2005 20 10 grade IV 
10 grade II 
2DGE, 
LC−ESI−MS/MS, 
Western Blot 
PBZ 15 2 
[33] 2005 13 GBs 2DGE PBZ 19 1 
[34] 2005 127 57 GBs 
22 grade III glioma 
29 grade II glioma 
MALDI-TOF 19 patients 
undergoing surgery 
for "non-neoplastic 
diseases" 
24 0 
[35] 2005 27 10 GBs 
14 grade III 
1 grade II 
2 grade I 
2DGE, MALDI-TOF 
MS 
EB 29 4 
[36] 2004 85 52 GBs 
13 grade III 
10 grade II 
10 epilepsy 
2DGE, MALDI-TOF 
MS 
PBZ 37 2 
[37] 2004 18 4 GBs 
2 oligo II 
2 AO grade III 
2 embryonal 
carcinoma 
1 pheochromocytoma 
1 DNET 
1 gemistocytic 
astrocytoma grade II 
MALDI-MS EB Identification 
of protein 
patterns 
without 
protein 
characterizati
on 
- 
[38] 2003 5 2 GBs 
2 grade III 
1 grade I 
2DGE, MALDI-TOF 
MS 
PBZ from the same 
patient 
15 1 
[39] 2003 4 4 GBs SELDI-TOF-MS None Identification 
of protein 
profiles 
without 
protein 
characterizati
on 
- 
[40] 2001 94 56 GBs 
13 AAIII 
25 low-grade gliomas 
Western Blot 
analysis 
Lysates from 16 
week old fetuses 
14 0 
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surgery for epilepsy after identification of the epileptic cradle using per-operative 
electroencephalograms and electrostimulation. 
Histological analysis and protein extraction were performed for each biopsy specimen. For 
histological analysis, formalin-fixed, paraffin-embedded sections of the biopsy specimens were 
stained with hematoxylin-phloxin-saffron.  
Tissue protein extraction 
Protein extracts of tissue samples were prepared as previously described [10]. Briefly, cell pellets 
from PBZ and EB samples were resuspended in cold lysis buffer (6 M guanidine HCl, pH 8.5, 
cells/buffer: 1/2.5(v/v)) and sonicated on dry ice with an ultrasonic processor (Bioblock Scientific, 
Illkirch, France) six times for 10 sec with 30 sec pauses between using a microtip setting power 
level at 40% pulse duration. The homogenates were centrifuged (15,000 g, 30 min, 4°C) and the 
resulting supernatants were then ultracentrifuged (105,000 g, 1 h, 4°C). Protein concentrations in 
the resulting supernatants were measured with a BioRad Protein Assay Kit (BioRad, Marnes-la-
Coquette, France) according to the manufacturer’s instructions. The samples from the three patients 
undergoing epilepsy surgery were pooled.  
ICPL labeling and protein digestion 
The experimental design and the ICPL method are described in Table 2. ICPL labeling was 
performed on 50 µg of PBZ or pooled EB samples as previously described (Com et al., 2012), 
according to the experimental design described in Table 2. Labeled proteins (50 µg) were separated 
by SDS-PAGE in 12% precast gels (GeBeGel, Gene Bio Application), which was then stained with 
Coomasie blue R-350 using the EZBlue gel staining reagent (Sigma-Aldrich, Saint Quentin 
Fallavier, France). Entire gel lanes were cut into 20 sections, which were washed in different 
ACN/100 mM NH4HCO3 solutions. In-gel digestion was performed overnight at 37°C with 
modified trypsin (Promega, Charbonnières-lès-Bains, France) following a previously described 
protocol (13). Proteolytic peptides were then extracted from the gel sections by sequential 
incubation in the following solutions: ACN/H20/TFA, 70:30:0,1 (v/v/v), 100% ACN and 
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ACN/H20/TFA, 70:30:0,1 (v/v/v), and the extracts were concentrated by evaporation down to a 
final volume of 30 µL. 
 
L M H
Reaction 1 EB pool GB3-PBZ GB16-PBZ
Reaction 2 GB10-PBZ EB pool GB25-PBZ
Reaction 3 GB22-PBZ GB26-PBZ EB pool  
 
Table 2: Experimental design of the ICPL labelling for each sample 
L: light ICPL reagent, M: medium ICPL reagent, H: heavy ICPL reagent, GB-PBZ: glioblastoma-peritumoral brain 
zone, EB pool: peripheral epilepsy surgery brain samples pooled from three patients. 
 
 
GLC-MS/MS analysis and protein identification and relative quantification 
Proteolytic mixtures were analyzed on a nano-HPLC system (Ultimate 3000, Dionex, Jouy-en-
Josas, France) coupled on-line with an Esquire HCT Ultra PTM Discovery mass spectrometer 
(Bruker Daltonik GmbH, Bremen, Germany), equipped with a nanoflow ESI source and an ion trap 
analyzer (ITMS) as previously described [10]. The EsquireControl™ software (Bruker Daltonik 
GmbH) automatically alterned MS and MS-MS acquisitions and was tuned to preferentially subject 
ICPL-labeled peptides to MS-MS acquisitions. DataAnalysis™ 3.4 software (Bruker Daltonik 
GmbH) was used to create the peak lists from raw data. For each acquisition, a maximum of 700 
compounds was detected with an intensity threshold of 100,000 and the charge state of precursor 
ions was automatically determined by resolved-isotope deconvolution. ProteinScape™ 2.0 software 
(Bruker Daltonik GmbH) was used to submit MS/MS data to the Swiss-Prot database (version 70, 
November 2011, Homo Sapiens taxonomy, 20257 sequence entries) and the randomized version of 
this database (decoy) to determine the false positive rate (FPR), defined as the number of validated 
decoy hits / (number of validated targets hits + number of decoy hits) * 100, using the Mascot 
algorithm (Mascot server v2.2, http://www.matrixscience.com) as previously described (Com et al., 
2012). Given that modification of lysine residues by ICPL labeling prevents their cleavage by 
trypsin, arginine C was selected as the enzyme with one allowed miscleavage. 
Carbamidomethylation of cysteines was set as a fixed modification, and labeling of lysine residues 
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by light (L), medium (M) or heavy (H) ICPL reagents, and methionine oxidation were considered as 
variable modifications. The mass tolerance for parent and fragment ions was set to 0.25 and 0.5 Da, 
respectively. Peptide identifications were accepted if the individual ion Mascot scores were above 
30 or above the identity threshold (the ion score is -10*log (p), where p is the probability that the 
observed match is a random event, p-value <0.05). The ProteinExtractor algorithm (14) was used to 
compile identified peptides to proteins as previously described [10]. Every protein reported was 
identified by at least one peptide with significant ion Mascot score (above the identity threshold) 
and which cannot be mapped to a higher-ranking protein already in the result list, and protein 
identifications were accepted if the FPR of the search was lower than 1%. 
WarpLC 1.2 software (Bruker Daltonik GmbH) was used for relative protein quantification; this 
software automatically calculates H/L, M/L and H/M ratios by comparing the relative intensities of 
m/z ratios corresponding to the labeled peptides observed on MS spectra using DataAnalysis 3.4 
software using previously described parameters [10]. The minimum differences in H/L, M/L, and 
H/M ratios associated with significant differences in protein expression were determined by 
calculating the technical variability of our system as previously described [10] and the significant 
threshold was fixed at 2 standard deviations from the normalized median of each H/L, M/L and 
H/M ratio; this gavethresholds od 1.41 for over-expressed proteins and 0.71 for under-expressed 
proteins (data not shown). 
Gene ontology term enrichment and network analysis 
The Annotation, Mapping, Expression end Network (AMEN) suite of software tools (16) was used 
to assess biological process GO term enrichment in the GB-PBZ / EB differential protein group 
using the International Protein Index human proteome for reference (release 3.8) (20). To be 
significantly over-represented in a group of genes, a GO term should have a p-value (adjusted with 
FDR by the Benjamin-Hochberg Method) lower than 0.01 and at least three proteins had to be 
associated with the annotation involved. A high Ontology Specific Information Rate (OSIR) cut-
off, ≥ 0.4, was selected to avoid redundancy between closely related terms. 
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The network representation was drawn using AMEN and seven protein interaction databases: 
IntAct (release 2010-03, http://www.ebi.ac.uk/intact), MINT (release 2010-03, 
http://160.80.34.4/mint/Welcome.do), BioGRID (release 2010-03, http://thebiogrid.org), DIP 
(release 2010-04, http://dip.doe-mbi.ucla.edu), HPRD (release 2010-04, http://www.hprd.org), 
CORUM (release 2010-04, http://mips.helmholtz-muenchen.de/genre/proj/corum), and MatrixDB 
(release 2010-04, http://matrixdb.ibcp.fr).  
 
Results and discussion 
This study is, to our knowledge, the first to compare the proteomic profiles of peritumoral brain 
zone tissue from GB and brain tissue samples obtained after epilepsy surgery to assess which is the 
most suitable for use as control samples for proteomic studies of GB.  
Macroscopically, PBZ samples are composed of a mixture of grey and white matters but the 
proportion of white matter is greater because of the usual localization of GB in the brain.. As GB is 
an highly infiltrative tumor, histological analysis of PBZ can show microsatelite tumors or isolated 
infiltrated GB cells. For all the samples included in this study, histological analysis indicated an 
infiltration of tumor cells in two PBZ samples only  (between 5-10%) (data not shown). However, 
this infiltration was too low to alter the genomic and proteomic profiles of PBZ. In fact, while array 
CGH analysis of TZ indicated gain of chromosome 7 and loss of chromosome 9 and 10, no such 
genomic aberrations were observed in corresponding PBZ (data not shown). As epileptic zone are 
usually cortical, EB samples are principally composed of grey matter with a small contingent of 
white matter. Consequently, these two types of brain tissue sample are divergent, with different 
cytoarchitectural organizations and containing different types of neural cells. 
We used the ICPL technique to compare the proteomes of these two types of brain tissue sample 
because it allows high-throughput, quantitative proteome profiling in an acurate and reproducible 
manner for up to four different samples [13]. Unlike other MS-based differential proteomic 
approaches, this technique can be applied both to cell cultures and to tissue samples and provides 
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information about protein isoforms [14, 15]. The ICPL technique is is also informative about non-
differential proteins thanks to the simultaneous quantification and identification. 
By querying the human Swiss-Prot database, we identified 197 non-redundant proteins with a score 
above the identity threshold and with a FDR < 1% (supplementary table 1). The numbers of 
identified and quantified proteins per patient are reported in Table 3. 
 
    PBZ/EB  
  
# identified 
proteins
b
  
# quantified 
proteins
c
 
< 0.71
d
 >0.71 and <1.41
e
 >1.41
f
 
 
GB3
a
 145 72 42 19 11  
GB10
a
 123 58 36 10 12  
GB16
a
 145 72 22 40 10  
GB22
a
 116 55 36 11 8  
GB25
a
 123 58 34 12 12  
GB26
a
 116 55 46 6 3  
 
Table 3: Number of identified and quantified proteins for each patient 
a
 The anonymous designation of each patient is reported in the first column, 
b
 Number of unique identified 
proteins, 
c
 Number of unique quantified proteins, 
d
 Number of unique quantified proteins with a ratio < 0.71 
(expression decrease above 41%), 
e
 Number of unique quantified proteins with a ratio > 0.71 and <1.41 (non 
modulated expression), 
f
 Number of unique quantified proteins with a ratio > 1.41 (expression increase 
above 41%) 
 
To assess the differential expression of proteins between PBZ and EB samples, we selected proteins 
with an average ratio, in six analyzed patients, of > 1.41 or < 0.71, with individual ratios > 1.41 or < 
0.71 in at least 3/6 patients with a minimum of two peptides in at least 50% of the patients. On this 
basis, we identified 35 proteins the expression of which differed between PBZ and EB. Most of 
these proteins (29/35 proteins, or 83%) were more weakly expressed in PBZ than EB, and only six 
were more strongly expressed (Table 4). 
AMEN software was used to evaluate GO term enrichment. The over-represented biological 
functions (p-value < 0.01) in EB are associated with energy metabolism, nervous sytem 
development, synaptic transmission, cellular transport and protein folding and processing (Figure 
1). We previously observed these biological functions as being up-regulated in GB biopsies by 
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comparison with PBZ samples used for reference [10]. Furthermore, we identified a functional 
network including 21 of the 35 proteins differentially expressed between PBZ and EB (Figure 2). 
 
 
Figure 1: Biological processes involving the differentially expressed proteins 
The color scale represents the down (in blue) or up-regulation (in red) with their respective corrected p-value for each 
GO term. Bold characters display a significant enrichment. 
 
An analysis of the literature revealed that some of the six proteins up-regulated in GB-PBZ are 
ubiquitous, components of basic cellular pathways like DNA folding for histones (HIST1H2AC and 
HIST1H4A) or involved in the regulation of the osmotic pressure of blood, such as albumin. We 
will not consider these proteins further. The up-regulation of the myelin basic protein (MBP) and 
the glial fibrillary acidic protein (GFAP) observed in PBZ may be related to the fact that this zone 
contain more white matter than EB. . Note, however, that two of the up-regulated proteins, the 
crystallin B -chain (CRYAB) and the histone H3F3A have known oncogenic roles.  
The histone H3F3A was not considered to be an oncogene until recently when two publications 
reported that it is a specific and reproducible marker of pontine GB [16, 17]. These articles 
document two mutations, K27M and G64V, in a large cohort of children with pediatric GB. They 
also report that the K27M mutation is preferentially associated with cases with older onset, during 
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teenage, and a hemispheric localization [16]. Therefore, the histone H3F3A up-regulation in GB-
PBZ/EB we observed is of interest. Possibly, this up-regulation could be the result of one of these 
mutations. Unfortunately, the tryptic peptides which would be mutated were not detected in our 
experiments. 
 
Figure 2: Interaction network representation of the differentially expressed proteins using the 
AMEN software 
 
CRYAB is the major protein of the eye lens and also a chaperone belonging to the small heat shock 
protein family. In the CNS, CRYAB has a protective role in autoimmune demyelination [18]. 
CRYAB has been found in various types of solid tumor as a novel protein and may serve as a 
prognostic marker [19, 20]. CRYAB is also modulated by hypoxia [21, 22] and regulates tumor 
angiogenesis [23]. 
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Our analysis of the literature for the 29 proteins up-regulted in EB versus PBZ indicated that only a 
few have a role in the pathogenesis of some forms of epilepsy: solute carrier family 25 member 6 
(SCL25A6), Ras-related C3 botulinum toxin substrate 3 (Rac3), TUBA1A, spectrin alpha chain 
(SPTAN1) and GAPDH. 
Surprisingly, we observed that several proteins over-expressed in EB have been implicated in the 
oncogenesis and in the pathophysological mechanisms of brain tumors; these proteins included 14-
3-3 proteins β and γ, the ATPase Na+/K+ transporting alpha-1 and alpha-2 polypeptides (ATP1A1 
and ATP1A2), GAPDH, the heat shock 70 kDa protein 8 (HSPA8), phosphatidylethanolamine 
binding protein 1 (PEBP1/RKIP) and the tubulin subtypes identified (TUBA1A, TUBA1B, 
TUBA4A, TUBAL3, TUBB, TUBB2A, TUBB3 and TUBB4). 
These various findings demonstrate that the proteomes of PBZ and EB differ, but that EB has a 
more “tumoral” protein expression pattern, whereas PBZ seemed to have a more conventional 
proteomic profile. The up-regulation of oncogenic proteins such as Fos and Jun has already been 
observed in the dendate gyrus of animal models of epilepsy [24, 25]. Therefore, in our opinion, 
PBZ appears to be a more suitable control tissue than EB for proteomic studies of GB. However, 
considering PBZ as a “normal” tissue is likely to be erroneous. GB generally recurs at the resection 
margin, strongly suggesting that the PBZ is not “normal” [3-5]. Furthermore, we have isolated a 
new cell population from PBZ; these cells, named GB-associated stromal cells (GASCs), have 
properties similar to those of cancer-associated fibroblasts (CAFs). Like CAFs, GASCs express 
mesenchymal markers and have tumor-promoting effects [26]. 
Post-mortem brain tissue obtained from autopsy is a potential alternative source of brain control 
samples. However, Skold and collaborators [27] showed that several highly abundant proteins are 
enzymatically degraded in the brain within minute of death, such that the proteome rapidly differs 
from that normally present in vivo. 
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Accessiona Protein Nameb # ratioc
geometric 
meand
CVe
ratio > 1.41 
or < 0,71 / # 
patientf
% ratio 
quantified 
with 1 
peptideg
Up-regulated proteins
CRYAB_HUMAN Alpha-crystallin B chain OS=Homo sapiens GN=CRYAB PE=1 SV=2 4 2,45 0,34 4/6 50%
H2A1C_HUMAN Histone H2A type 1-C OS=Homo sapiens GN=HIST1H2AC PE=1 SV=3 4 2,43 0,35 3/6 50%
H33_HUMAN Histone H3.3 OS=Homo sapiens GN=H3F3A PE=1 SV=2 6 2,13 1,13 4/6 0%
H4_HUMAN Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 6 2,05 0,81 4/6 0%
ALBU_HUMAN Serum albumin precursor - Homo sapiens (Human) 6 2,04 1,01 4/6 0%
GFAP_HUMAN Glial fibrillary acidic protein OS=Homo sapiens GN=GFAP PE=1 SV=1 6 1,70 0,87 4/6 0%
MBP_HUMAN Myelin basic protein OS=Homo sapiens GN=MBP PE=1 SV=3 6 1,27 0,61 3/6 0%
Down-regulated proteins
PRDX2_HUMAN Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 6 0,81 0,56 3/6 0%
ENOA_HUMAN Alpha-enolase - Homo sapiens (Human) 6 0,71 0,41 3/6 0%
CLH1_HUMAN Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 6 0,66 0,26 3/6 33%
DYN1_HUMAN Dynamin-1 OS=Homo sapiens GN=DNM1 PE=1 SV=2 4 0,66 0,43 3/6 0%
1433B_HUMAN 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 4 0,58 0,50 3/6 0%
1433G_HUMAN 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 6 0,58 0,37 4/6 0%
TBA4A_HUMAN Tubulin alpha-4A chain OS=Homo sapiens GN=TUBA4A PE=1 SV=1 6 0,57 0,57 4/6 0%
TBB3_HUMAN Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 6 0,56 0,40 5/6 0%
PEBP1_HUMAN Phosphatidylethanolamine-binding protein 1 - Homo sapiens (Human) 4 0,56 0,24 3/6 50%
TBB4_HUMAN Tubulin beta-4 chain OS=Homo sapiens GN=TUBB4 PE=1 SV=2 6 0,56 0,36 5/6 0%
ADT3_HUMAN ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4 4 0,55 0,35 3/6 50%
RAC3_HUMAN Ras-related C3 botulinum toxin substrate 3 OS=Homo sapiens GN=RAC3 PE=1 SV=1 4 0,54 0,42 3/6 50%
TBB5_HUMAN Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 4 0,54 0,39 3/6 0%
TBA1A_HUMAN Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 6 0,53 0,54 5/6 0%
TBA1B_HUMAN Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 6 0,53 0,54 5/6 0%
TBB2A_HUMAN Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A PE=1 SV=1 6 0,51 0,39 5/6 0%
GBB2_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 OS=Homo sapiens GN=GNB2 PE=1 SV=3 4 0,50 0,39 4/6 50%
AT1A3_HUMAN Sodium/potassium-transporting ATPase subunit alpha-3 OS=Homo sapiens GN=ATP1A3 PE=1 SV=3 6 0,50 0,27 6/6 0%
TBAL3_HUMAN Tubulin alpha chain-like 3 OS=Homo sapiens GN=TUBAL3 PE=1 SV=2 4 0,48 0,29 4/6 50%
G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase - Homo sapiens (Human) 4 0,48 0,42 4/6 0%
AT1A2_HUMAN Sodium/potassium-transporting ATPase subunit alpha-2 OS=Homo sapiens GN=ATP1A2 PE=1 SV=1 4 0,47 0,32 4/6 50%
ATPA_HUMAN ATP synthase subunit alpha, mitochondrial precursor - Homo sapiens (Human) 6 0,46 0,39 5/6 33%
HSP7C_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 4 0,46 0,29 4/6 0%
SPTA2_HUMAN Spectrin alpha chain, brain - Homo sapiens (Human) 4 0,45 0,24 4/6 0%
AT1A1_HUMAN Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=ATP1A1 PE=1 SV=1 6 0,44 0,31 6/6 0%
GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 OS=Homo sapiens GN=GNB1 PE=1 SV=3 6 0,43 0,41 6/6 0%
KCRB_HUMAN Creatine kinase B-type OS=Homo sapiens GN=CKB PE=1 SV=1 4 0,42 0,24 4/6 0%
AT1B1_HUMAN Sodium/potassium-transporting ATPase subunit beta-1 OS=Homo sapiens GN=ATP1B1 PE=1 SV=1 4 0,30 0,42 4/6 0%
PBZ/EB
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Table 4: Selection of proteins differentially expressed between PBZ and EB samples. 
a
 Swiss-Prot accession number, 
b
 Protein name, 
c
 Number of observed ratios, 
d
 Geometric mean of the observed ratios, 
e
 Coefficient of variation of the observed ratios, 
f
 Number of 
patient ratio > 1.41 or < 0,71  compared to the total number of analyzed patient, 
g
 Percentage of ratio quantified with more than one peptide
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Conclusion 
The PBZ and EB have each a specific protein expression pattern. This has consequences for the 
interpretation of proteomic data obtained using these types of tissues as control samples. In our 
opinion, PBZ may be more suitable control tissue for differential proteomic analysis. However, this 
tissue should not be considered to be “normal” tissue and other alternatives should be sought. 
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